Celldex amends bylaws to implement proxy access for shareholders

Celldex Therapeutics, Inc.

Board approved proxy access on Jan 25, 2022, adding Article III Section 13 to bylaws.
Stockholders or group owning at least 3% of stock continuously for 3 years may nominate directors.
Maximum nominees is greater of 2 individuals or 20% of board, subject to requirements.
Proxy access will first apply for the 2023 annual meeting of shareholders.
Full amendment text filed as Exhibit 3.1 to this 8-K.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.